Bcantt 2024 Bladder Cancer Surveillance Is Less More After the bcan patient advocates shared their bladder cancer journeys, dr. mary beth westerman provided an overview of contemporary surveillance regimens and tools for bladder cancer patients. Bcantt 2024: bladder cancer surveillance: is less more? were you unable to attend 2024 bladder cancer advocacy network (bcan) think tank? get all of the groundbreaking research, new guidelines, and the latest advances in urologic medicine you missed.
Bcantt 2024 Bladder Cancer Surveillance Is Less More In this study, we reviewed the results of several previous studies to understand how safe and effective active surveillance is for patients with early stage bladder cancer. we found that for carefully chosen patients, active surveillance can be a safe and practical option. In this study, we reviewed the results of several previous studies to understand how safe and effective active surveillance is for patients with early stage bladder cancer. we found that for carefully chosen patients, active surveillance can be a safe and practical option. Xpert bladder cancer monitor is more sensitive but less specific compared to urine cytology. heterogeneity in the included studies is an important limitation of this study. Intravenous urography (ivu) is an alternative if ct is not available [90], but ct urography provides more information particularly in muscle invasive tumours of the bladder and in utucs (including status of lymph nodes and neighbouring organs).
Bcantt 2024 Bladder Cancer Surveillance Is Less More Xpert bladder cancer monitor is more sensitive but less specific compared to urine cytology. heterogeneity in the included studies is an important limitation of this study. Intravenous urography (ivu) is an alternative if ct is not available [90], but ct urography provides more information particularly in muscle invasive tumours of the bladder and in utucs (including status of lymph nodes and neighbouring organs). While active surveillance has become the standard treatment for low risk prostate cancer, this therapeutic option remains marginal in bladder cancer, as in kidney cancer. Non muscle invasive bladder cancer (nmibc) is managed initially with transurethral resection of a bladder tumor (turbt), followed by a risk stratified approach to adjuvant intravesical therapy (ive), and is associated with an overall survival of 90%. Despite improvements in survival rates due to advances in early detection, robotic surgery, and immunotherapy, bladder cancer continues to be a significant and increasing contributor to the global cancer burden. Surveillance of nmibc with flexible blc could detect more suspicious lesions and consequently more tumour recurrences compared to flexible wlc, with a increase in the rate of false positives leading to overtreatment.
Comments are closed.